Ying Chao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying Chao has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Milan Makale
Translational Neuro-Oncology Laboratories, Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA
3 shared publications - Natsuko Nomura
Translational Neuro-Oncology Laboratories, Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA
3 shared publications - Pengfei Jiang
Translational Neuro-Oncology Laboratories, Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA
3 shared publications - Rajesh Mukthavaram
Translational Neuro-Oncology Laboratories, Moores Cancer Center, UC San Diego, La Jolla, CA 92093, USA
3 shared publications - Santosh Kesari
Department of Translational Neurosciences and Neurotherapeutics, Pacific Neuroscience Institute and John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA 90404, USA
3 shared publications - Shireen Vali
Cellworks Group, Inc., San Jose, CA, USA
3 shared publications
Latest Publications
- Open Access
- 21 May 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 128
In silico modeling predicts drug sensitivity of patient-derived cancer cells
Glioblastoma (GBM) is an aggressive disease associated with poor survival. It is essential to account for the complexity of GBM biology to improve diagnostic and therapeutic strategies. This complexity is best represented by the increasing amounts of profiling (“omics”) data available due to advances in biotechnology. The challenge of integrating these vast genomic and proteomic data can be addressed by a comprehensive systems modeling approach.
- 21 May 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 128
Open AccessIn silico modeling predicts drug sensitivity of patient-derived cancer cells
Glioblastoma (GBM) is an aggressive disease associated with poor survival. It is essential to account for the complexity of GBM biology to improve diagnostic and therapeutic strategies. This complexity is best represented by the increasing amounts of profiling (“omics”) data available due to advances in biotechnology. The challenge of integrating these vast genomic and proteomic data can be addressed by a comprehensive systems modeling approach.
- Open Access
- 13 May 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 126
Erratum to: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
- 13 May 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 126
Open AccessErratum to: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
- Open Access
- 17 January 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 13
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH clinical collection (NCC) that includes 446 FDA-approved drugs, with the goal of identifying new GBM therapeutics for rapid entry into clinical trials for GBM.
- 17 January 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 13
Open AccessNovel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Glioblastoma (GBM) is a therapeutic challenge, associated with high mortality. More effective GBM therapeutic options are urgently needed. Hence, we screened a large multi-class drug panel comprising the NIH clinical collection (NCC) that includes 446 FDA-approved drugs, with the goal of identifying new GBM therapeutics for rapid entry into clinical trials for GBM.